Clinical and Radiological Factors Affecting Progression in Sarcoidosis
Keywords:
Sarcoidosis, Progression, Lymph NodeAbstract
Background and aim: To determine the clinical and radiological indicators of disease progression in a newly diagnosed sarcoidosis patient.
Methods: The data of patients who were diagnosed with sarcoidosis in our department between January 2014 and June 2022 were analyzed. The patients were divided into two groups: progression and non-progression.
Groups were compared according to symptoms at the time of diagnosis, comorbidities, foci of extrapulmonary involvement, shape, size, density, and localization of mediastinal lymph nodes, parenchymal findings, disease stage and whether or not treatment was received at the beginning.
Results: The study included 292 sarcoidosis patients. The number of patients who progressed was 46 (15.8%). It was observed that stage II patients progressed more than stage I patients (p<0,001).
The mean time to progression was 38.05±30.45 months in stage I and 28±58 months in stage II patients. Progression rate was higher in patients with right upper paratracheal, subaortic-paraaortic, subcarinal LAP (p= 0.010, p= 0.012, p= 0.020, respectively). The higher number of stations with LAP was associated with the presence of progression (p=0.017). The presence of parenchymal nodules (29/64.4%) and the number of lobes with nodules was also associated with progression (p= 0.027, 0.022, respectively). Progression rate was 76.1% in patients with treatment indication at the time of diagnosis (p<0.001).
Conclusions: Disease stage is a prognostically important factor in the course of sarcoidosis, which is supported by our study results. Accordingly, it is important to follow patients with high-stage sarcoidosis more closely and to identify patients with treatment indications in time.
References
Seve P, Pacheco Y, Durupt F, Jamilloux Y, Gerfaud-Valentin M, Isaac S, Boussel L, Calender A, Androdias G, Valeyre D, El Jammal T. Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis. Cells 2021;10:766
Malkova A, Zinchenko Y, Starshinova A, Kudlay D, Kudryavtsev I, Glushkova A, Yablonskiy P, Shoenfeld Y. Sarcoidosis: Progression to the chronic stage and pathogenic based treatment (narrative review). Front Med (Lausanne). 2022(6);9:963435
Belperio JA, Fishbein MC, Abtin F, Channick J, Balasubramanian SA, Lynch III JP. Pulmonary sarcoidosis: A. comprehensive review: Past to present. Journal of Autoimmunity. December 2024;149:103107
Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, Abston E, Bernstein RC, Blankstein R, Chen ES, Culver DA, Drake W, Drent M, Gerke AK, Ghobrial M, Govender P, Hamzeh N, James WE, Judson MA, Kellermeyer L, Knight S, Koth LL, Poletti V, Raman SV, Tukey MH, Westney GE, Baughman RP. Sarcoidosis diagnosis and detection An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;8:e26-e51
Peros-Golubicic T, Ivicevic A, Bekić A, Alilovic M, Tekavec-Trkanjec J, i Smojver-Jezek S. Lung lavage neutrophils, neutrophil elastase and albumin in the prognosis of pulmonary sarcoidosis. Preuzeto S, editor. Coll Antropol. 2001;25:349-55
Feng H, Yan L, Zhao Y, Li Z, Kang J. Neutrophils in bronchoalveolar lavage fluid indicating the severity and relapse of pulmonary sarcoidosis. Front Med. 2022; 8:3125
Drent M, Jacobs JA, de Vries J, Lamers RJS, Liem IH, Wouters EFM. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J. 1999;13:1338-44
Zİegenhagen MW, Benner UK, Zıssel G, Zabel P, Schlaak M, Müller-Quernheım J. Sarcoidosis: TNF Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers. Am j Respir Crit Care Med. 1997;156:1586-1592
Bergantini L, Bianchi F, Cameli P, Mazzei MA, Fui A, Sestini P, et al. Prognostic biomarkers of sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme, and KL-6. Dis Markers. 2019:8565423
Casal A , Suarez-Antelo J, Soto-Feijóo R , Ferreiro L , Rodríguez-Nunez N, Lama A, Riveiro V, Toubes ME, Lourido T, Ricoy J, Rabade C, Zamarrón C, Rodriguez C, Abelleira R, Alvarez-Dobaño JM, Golpe A, Martinez de Alegría A, Antúnez JR, Gude F, Valdes L. Sarcoidosis. Disease progression based on radiological and functional courses: predictive factors. Heart Lung. 2022;56:62-69
Silva AL, Melo N, Mota PC, Lima B, Pereira JM, Cunha R, Guimaraes S, Conceiçao Souto-Moura C, Morais A. Pulmonary Sarcoidosis: Prognostic Factors at Diagnosis in Patients from North of Portugal. Reumatol Clin (Engl Ed). 2020 Nov-Dec;16(6):468-472
Criado E, Sánchez M, Ramírez J, et al. Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation. Radiographics 2010;30:1567-86
Koc AS, Oncel G, Ince O, Sever F, Kobak S. The role of chest X-ray in the early diagnosis and staging of sarcoidosis: Is it really should be done? Reumatologia Clinica. 2023;19:560-564
Castro MDC, de Castro Pereira CA, Soares MR. Prognostic features of sarcoidosis course in a Brazilian cohort. J Bras Pneumol. 2022;48(1):e20210366
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
